Leaderboards/Immunodeficiency and Autoimmune Disorders

Immunodeficiency and Autoimmune Disorders

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Researchers

1
O’Jay Stewart
Columbia University Irving Medical Center
2
Chieh-Yu Liang
Washington University in St. Louis
3
Louise Malle
Columbia University Irving Medical Center
4
Zachary Walsh
Columbia University Irving Medical Center
5
Leanne P. M. van Leeuwen
Erasmus University Rotterdam
6
Valentina Raglianti
European Society for Sexual Medicine
7
Jule Taubmann
Universitätsklinikum Erlangen
8
Clara Young
Garvan Institute of Medical Research
9
Samuel J. Starke
Rush University
10
Chihiro Ishiwatari-Ogata
Taisho Pharmaceutical (Japan)

Papers

1
Imprinting of serum neutralizing antibodies by Wuhan-1 mRNA vaccines
Nature|2024
81 cit.
2
Monoallelic expression can govern penetrance of inborn errors of immunity
Nature|2025
72 cit.
3
Anti-slit diaphragm antibodies on kidney biopsy identify pediatric patients with steroid-resistant nephrotic syndrome responsive to second-line immunosuppressants
Kidney International|2024
61 cit.
4
Anti-slit Antibodies against Podocin and Kirrel1 in Pediatric and Adult Podocytopathies
Journal of the American Society of Nephrology|2025
37 cit.
5
Orthopoxvirus-specific antibodies wane to undetectable levels 1 year after MVA-BN vaccination of at-risk individuals, the Netherlands, 2022 to 2023
Eurosurveillance|2024
18 cit.
6
Bloodstream Infections and Colonization in Hematopoietic Stem Cell Transplant Recipients at a South African Center: A Retrospective Analysis
Transplantation and Cellular Therapy|2025
9 cit.
7
Immunogenicity of COVID-19 booster vaccination in IEI patients and their one year clinical follow-up after start of the COVID-19 vaccination program
Frontiers in Immunology|2024
8 cit.
8
Anti-nephrin, anti-podocin and anti-Kirrel1 antibodies: biological challenges and clinical implications
Nephrology Dialysis Transplantation|2025
7 cit.
9
Langzeitverlauf von Effizienz und Sicherheit der CD19-CAR T-Zell-Therapie beim systemischen Lupus erythematodes
Zeitschrift für Rheumatologie|2025
5 cit.
10
Long-term effects of COVID-19 in patients with primary immunodeficiency: An IPOPI worldwide survey
Journal of Allergy and Clinical Immunology|2025
3 cit.

Emerging Leaders

Drafting the new consensus

Researchers

1
Alexandre Bolze
Helix (United States)
2
Paul Bastard
Inserm
3
Marcela Moncada‐Vélez
Universidad de Antioquia
4
Masato Ogishi
Rockefeller University
5
Jérémie Rosain
Inserm
6
Yu Zhang
Kunming University of Science and Technology
7
Huie Jing
Office of Extramural Research
8
Adam Klocperk
Ocní klinika
9
Qinhua Zhou
Children's Hospital of Fudan University
10
Christelle Tual
Inserm

Papers

1
Human IRF1 governs macrophagic IFN-γ immunity to mycobacteria
Cell|2023
115 cit.
2
SARS-CoV-2 variant Delta rapidly displaced variant Alpha in the United States and led to higher viral loads
Cell Reports Medicine|2022
90 cit.
3
Evidence for SARS-CoV-2 Delta and Omicron co-infections and recombination
Med|2022
85 cit.
4
Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs
Science Immunology|2022
77 cit.
5
A loss-of-function <i>IFNAR1</i> allele in Polynesia underlies severe viral diseases in homozygotes
The Journal of Experimental Medicine|2022
67 cit.
6
Impaired IL-23–dependent induction of IFN-γ underlies mycobacterial disease in patients with inherited TYK2 deficiency
The Journal of Experimental Medicine|2022
67 cit.
7
HLA-A∗03:01 is associated with increased risk of fever, chills, and stronger side effects from Pfizer-BioNTech COVID-19 vaccination
Human Genetics and Genomics Advances|2022
55 cit.
8
Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children
The Journal of Experimental Medicine|2024
39 cit.
9
Inherited human ITK deficiency impairs IFN-γ immunity and underlies tuberculosis
The Journal of Experimental Medicine|2022
29 cit.
10
Impaired development of memory B cells and antibody responses in humans and mice deficient in PD-1 signaling
Immunity|2024
23 cit.

Current Senior Leaders

Wrote the book, still writing it

Researchers

1
Jean‐Laurent Casanova
Howard Hughes Medical Institute
2
Bodo Grimbacher
University Medical Center Freiburg
3
Alain Fischer
Inserm
4
Vijay K. Kuchroo
Broad Institute
5
Thomas J. Kipps
University of California San Diego
6
Stuart G. Tangye
Garvan Institute of Medical Research
7
Robert A. Good
Technology Information, Forecasting and Assessment Council
8
Charlotte Cunningham‐Rundles
Icahn School of Medicine at Mount Sinai
9
Steven M. Holland
National Institute of Allergy and Infectious Diseases
10
Luigi D. Notarangelo
Harvard University

Papers

1
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells
Nature|2006
6.9k cit.
2
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
Blood|2008
3.2k cit.
3
Autoantibodies against type I IFNs in patients with life-threatening COVID-19
Science|2020
2.8k cit.
4
Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
Science|2000
2.6k cit.
5
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
Nature Immunology|2005
2k cit.
6
IL-21 initiates an alternative pathway to induce proinflammatory TH17 cells
Nature|2007
1.8k cit.
7
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
Blood|2018
1.7k cit.
8
B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy
Cell|1995
1.7k cit.
9
Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease
Nature|2002
1.6k cit.
10
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
New England Journal of Medicine|2015
1.6k cit.

Reagents for Immunodeficiency and Autoimmune Disorders

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Cell Signaling TechnologyEvidence 66

Rab1A (D3X9S) Rabbit Monoclonal Antibody

Cited in 5 papers
#13075$161,351
View Evidence →
Cell Signaling TechnologyEvidence 67

Total RIP3 Matched Antibody Pair II

Cited in 5 papers
#19570$1,726
View Evidence →
Thermo Fisher ScientificEvidence 69

JAK2 Recombinant Rabbit Monoclonal Antibody (K01_2U25)

Cited in 5 papers
#MA565738
View Evidence →

🌟 All-Time

Most validated

Thermo Fisher ScientificEvidence 75

IL-4 Monoclonal Antibody (E10022)

Cited in 5 papers
#M2IL4I
View Evidence →
RocklandEvidence 68

Anti-KANK2 (RABBIT) Antibody - 600-401-CD3

Cited in 5 papers
#600-401-CD3
View Evidence →
Thermo Fisher ScientificEvidence 69

JAK2 Recombinant Rabbit Monoclonal Antibody

Cited in 5 papers
#RAB02515
View Evidence →